Repetitive intravenous dihydroergotamine as therapy for intractable migraine
- 1 July 1986
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 36 (7) , 995
- https://doi.org/10.1212/wnl.36.7.995
Abstract
For patients with chronic intractable headache, we compared a new treatment and a traditional one. Fifty-five patients (36 dependent on ergotamine, analgesics, diazepam, or corticosteroids) were given IV dihydroergotamine (DHE) and metoclopramide every 8 hours. Fifty-four age- and sex-matched patients (38 drug-dependent) were given diazepam intravenously every 8 hours. Forty-nine of the 55 DHE-treated patients became headache-free within 48 hours, and 39 of them sustained benefits in a mean follow-up of 16 months. In contrast, 7 diazepam-treated patients became free of headache within 3 to 6 days, and 31 had improved somewhat in 10 days. Repetitive IV DHE helps to terminate cycles of intractable migraine.This publication has 4 references indexed in Scilit:
- Investigation of the venoconstrictor effect of 8? hydroxydihydroergotamine, the main metabolite of dihydroergotamine, in manEuropean Journal of Clinical Pharmacology, 1984
- Elucidation of the structure and receptor binding studies of the major primary, metabolite of dihydroergotamine in manEuropean Journal of Clinical Pharmacology, 1984
- Transformation of Episodic Migraine Into Daily Headache: Analysis of FactorsHeadache: The Journal of Head and Face Pain, 1982
- Dihydroergotamine binding to rat brain membranesLife Sciences, 1976